Wilson Disease Clinical Trial
Official title:
Oral Health and Wilson's Disease: SOMAWI
Patients with Wilson disease have poorer dental and periodontal health and a have lower oral quality of life than control patients. Patients with a neurological form would also more frequently present limitations in the function of the masticatory apparatus. Systemic treatments for Wilson disease are associated with lesions of the oral mucosa. Analysis of copper level in saliva could testify to the effectiveness of copper depletion in treated patients The main objective is to compare the state of dental health between: patients with Wilson disease in the hepatic form and patients with the neurological form, and a population of controls.
The comparaison between the three groups is based on evaluation criteria wich is CAOD index of caries severity (developed by Klein and Palmer in 1940) counting the number of permanent teeth with caries (evolving to include non-cavitary caries) (C), absent due to caries (A) and filled (O) in an individual. The maximum score is 28 (third molars are not taken into account). The index is obtained from clinical examination and panoramic dental imaging. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04573309 -
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
|
Phase 2 | |
| Completed |
NCT03539952 -
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
|
Phase 3 | |
| Active, not recruiting |
NCT04884815 -
Study of UX701 Gene Transfer for the Treatment of Wilson Disease
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03659331 -
A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease
|
N/A | |
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Completed |
NCT04965571 -
Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
|
||
| Terminated |
NCT05047523 -
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
|
Phase 3 | |
| Completed |
NCT04526210 -
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
|
Phase 1 | |
| Completed |
NCT00004338 -
Study of Zinc for Wilson Disease
|
Phase 4 | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Completed |
NCT02273596 -
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
|
Phase 2 | |
| Completed |
NCT02763215 -
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
|
||
| Completed |
NCT04408300 -
Study of Retinal Vascular Parameters in Patients With Wilson's Disease
|
N/A | |
| Recruiting |
NCT05783687 -
Real World Evidence Study in Subjects With Wilson's Disease
|
||
| Terminated |
NCT04909346 -
Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
|
||
| Completed |
NCT03867526 -
Establishment of Human Cellular Disease Models for Wilson Disease
|
||
| Enrolling by invitation |
NCT03589820 -
Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver Failure
|
N/A | |
| Completed |
NCT04526197 -
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
|
Phase 1 | |
| Completed |
NCT04910581 -
rTMS in Wilson Disease Dysarthria
|
N/A | |
| Active, not recruiting |
NCT02426905 -
Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
|
Phase 4 |